GEN Exclusives

More »

GEN News Highlights

Back to Item »

Australia Approves Biogen Idec’s Fampyra for Improving Walking Ability in Multiple Sclerosis

FDA-approved oral calcium-channel blocker is being developed under license from Acorda Therapeutics in non-U.S. markets.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?